Dow Up0.15% Nasdaq Up0.21%

Fidelity Advisor Biotechnology C (FBTCX)

19.85 Up 0.13(0.66%) Sep 17

Profile as of Aug 30, 2014Get Profile for:
Fidelity Advisor Biotechnology C
Fidelity Advisor Series VII82 Devonshire StreetBoston, MA 02109
Map
Phone: 877-208-0098
Fund Overview 
Category:Health
Fund Family:Fidelity Investments
Net Assets:1.74B
Year-to-Date Return:19.98%
Yield:0.00%
Morningstar Rating:4 stars
Fund Inception Date:Dec 27, 2000
Morningstar Style Box 
Health
[View Category Definition]
View Top Health Funds
About the Morningstar Style Box
Management Information 
Rajiv Kaul
Lead Manager since Oct 12, 2005
Kaul is a portfolio manager with Fidelity Investments. Since joining Fidelity Investments in 1996, he has worked as a research analyst and portfolio manager. Kaul also manages another Fidelity fund. He is the recipient of the Kann Rasmusson Environment Award, the Dean's Summer Research Award and a Ford Undergraduate Fellowship.
Investment Information 
Min Initial Investment:2,500
Min Initial Investment, IRA:500
Min Initial Investment, AIP:2,500
Min Subsequent Investment:N/A
Min Subsequent Investment, IRA:N/A
Min Subsequent Investment, AIP:100
FBTCX can be purchased from 63 brokerages.

Fund Summary 
The investment seeks capital appreciation. The fund invests primarily in common stocks. It normally invests at least 80% of assets in securities of companies principally engaged in the research, development, manufacture, and distribution of various biotechnological products, services, and processes, and companies that benefit significantly from scientific and technological advances in biotechnology. The fund invests in domestic and foreign issuers. It uses fundamental analysis of factors such as each issuer's financial condition and industry position, as well as market and economic conditions, to select investments. The fund is non-diversified.

Fund Operations 
Last Dividend : 0.00
Last Cap Gain (Sep 4, 2014) : 0.00
Annual Holdings Turnover (Sep 15, 2014) : 22.00%
Average for Category:51.88%
Fees & Expenses 
ExpenseFBTCXCategory Avg
Annual Report Expense Ratio (net):1.87%1.39%
Prospectus Net Expense Ratio:1.88%N/A
Prospectus Gross Expense Ratio:1.88%N/A
Max 12b1 Fee:1.00%N/A
Max Front End Sales Load:N/A5.28%
Max Deferred Sales Load: 1.00%2.37%
3 Yr Expense Projection*:591669
5 Yr Expense Projection*:1,0161,046
10 Yr Expense Projection*:2,2012,047
* Per $10,000 invested